Welcome to our dedicated page for Lifevantage Corporation news (Ticker: LFVN), a resource for investors and traders seeking the latest updates and insights on Lifevantage Corporation stock.
Lifevantage Corporation Common Stock (Delaware) (symbol: LFVN) is a pioneering company in the field of nutrigenomics, a cutting-edge area of nutritional science focused on how nutrients affect gene expression to improve health and wellness. Founded on the premise that aging is inevitable but can be managed, Lifevantage offers a range of products designed to combat the effects of aging and promote overall well-being.
The company's core business involves the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. Among its flagship offerings is Protandim, a scientifically-validated dietary supplement known for its ability to reduce oxidative stress. Other notable products include the LifeVantage TrueScience anti-aging skincare line, Axio energy drink mixes, PhysIQ weight management systems, and Canine Health, a pet supplement formulated to improve the health of dogs.
Lifevantage's products are available in multiple regions, including the United States, Japan, Hong Kong, Australia, Canada, the Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands. This geographical diversification helps the company reach a broad audience and sustain its growth trajectory.
Recently, Lifevantage has made significant strides in its business operations. Hundreds of independent consultants hosted virtual watch parties to kickstart the company's initiatives for 2024. The company also continues to innovate, as seen in the second quarter of fiscal 2024 results and the upcoming launch of its Evolve Compensation Plan and Rewards Circle customer loyalty program on February 1, 2024. These initiatives are designed to enhance customer satisfaction and drive business growth.
Financially, Lifevantage is committed to transparency and accountability, regularly updating investors on its performance through detailed reports and investor relations contacts. Despite the challenges posed by COVID-19, the company has maintained a resilient stance, focusing on future growth and product expansion.
Overall, Lifevantage remains a significant player in the health and wellness industry, continually advancing the science of nutrigenomics to offer effective solutions for aging and other health-related concerns.
LifeVantage Corporation (Nasdaq: LFVN) announced a five-year donation commitment to the Linus Pauling Institute (LPI) at Oregon State University, contributing to the LPI Research Innovation Fund. This partnership aims to enhance health through nutrition research. Senior VP Dr. Brian Dixon will join LPI's Director’s Circle, providing strategic insight. The collaboration allows LifeVantage to access third-party research and engage with leading researchers, aligning both organizations' goals of optimizing health through innovative nutrition.
LifeVantage Corporation (Nasdaq: LFVN) announced its fourth quarter and full year financial results for fiscal 2021, reporting revenue of $220.2 million, a 5.5% decline from the previous year. The fourth quarter revenue reached $54.8 million, down 7.7% year-over-year but up 6.2% sequentially. Adjusted EPS for Q4 was $0.31, up 10.7%. The company repurchased 1.2 million shares for $11.9 million and has a solid balance sheet with $23.2 million in cash and no debt. Guidance for fiscal 2022 forecasts revenue between $225 million and $235 million.
LifeVantage Corporation (Nasdaq: LFVN) is set to announce its financial results for Q4 and full fiscal year ending June 30, 2021, on August 19, 2021, after market close. A conference call with investors will follow at 2:30 p.m. MT. Interested parties can join by calling (877) 705-6003 for U.S. participants or (201) 493-6725 internationally. A replay of the call will be available until August 26, 2021. The company specializes in nutrigenomics and offers a range of health products, including dietary supplements and skincare lines.
LifeVantage Corporation (LFVN) reported Q3 fiscal 2021 results with revenue of $51.6 million, an 8.0% decline year-over-year and a 12.6% sequential drop. Active accounts decreased by 4.0% from last year. Notably, adjusted EPS rose by 53.8% to $0.20 despite challenges from COVID-19 supply chain disruptions. Gross profit decreased 8.8% to $42.8 million, and adjusted EBITDA fell 5.7% to $4.8 million. The company maintains a strong balance sheet with $19.0 million in cash and no debt, while updating its fiscal 2021 revenue guidance to $220-$223 million.
LifeVantage Corporation (Nasdaq: LFVN) will disclose its Q3 financial results for the period ending March 31, 2021, on April 29, 2021. Following the release, a conference call is scheduled for 2:30 p.m. MT (4:30 p.m. ET) to discuss the results. Interested investors can join via phone or listen to a live webcast on the company's website. A replay of the call will be available until May 6, 2021. LifeVantage specializes in Nutrigenomics, focusing on dietary supplements and skincare products, including its Protandim® line.
LifeVantage Corporation (Nasdaq: LFVN) will disclose its financial results for Q2 ending December 31, 2020, on February 2, 2021, after market closure. A conference call will occur at 2:30 PM MT (4:30 PM ET) that day for investors. Participants can join by calling (877) 705-6003 or (201) 493-6725 for international access. A replay will be available post-call until February 9, 2021. LifeVantage specializes in Nutrigenomics and offers various nutraceuticals and personal care products, including Protandim® and TrueScience®.
LifeVantage Corporation (Nasdaq: LFVN) reported its first quarter fiscal 2021 results, achieving adjusted EPS of $0.25, up 92.3% year-over-year. Total revenue reached $54.8 million, a 2.5% decline from the previous year, primarily due to the absence of an Elite Academy event. Active accounts decreased by 3.9% sequentially. Gross profit was $45.4 million, 82.9% of revenue. Adjusted EBITDA increased by 42.5% to $6.7 million. The company maintains a strong balance sheet with $18 million in cash and no debt. Guidance for fiscal 2021 remains unchanged, projecting revenue of $240-$251 million.
LifeVantage Corporation (Nasdaq: LFVN) will announce its financial results for the first quarter ended September 30, 2020, on November 3, 2020, after market close. A conference call for investors is scheduled for 2:30 p.m. MT. Interested participants can join by calling (877) 705-6003, with a replay available until November 10. The event will also be webcast live on the company's website. LifeVantage specializes in Nutrigenomics, offering a variety of nutraceutical supplements and skin care products, including its popular Protandim® line.
LifeVantage Corporation (Nasdaq: LFVN) announced the resignation of CEO Darren Jensen on September 3, 2020, with Chief Financial Officer Steven Fife appointed as the interim CEO. The Board is seeking a permanent successor. The company's sales and marketing teams will merge, led by Chief Sales Officer Justin Rose. LifeVantage reaffirmed its fiscal 2021 guidance, expecting revenue of $240 million to $251 million, adjusted EBITDA of $25 million to $27 million, and adjusted earnings per share between $0.87 and $0.91, while noting potential impacts from the evolving COVID-19 pandemic.
LifeVantage Corporation (Nasdaq: LFVN) announced that CEO Darren Jensen and CFO Steve Fife will participate in two upcoming virtual investor conferences. The LD Micro 500 conference is scheduled for September 1-4, with a presentation on September 2 at 9:20 a.m. MT. They will also attend the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, presenting on September 15. Both presentations will be available via webcast on the company’s investor relations website.
FAQ
What is the current stock price of Lifevantage Corporation (LFVN)?
What is the market cap of Lifevantage Corporation (LFVN)?
What does Lifevantage Corporation do?
What are some of the key products offered by Lifevantage?
In which regions are Lifevantage's products sold?
What recent achievements has Lifevantage made?
How does Lifevantage contribute to the field of nutrigenomics?
What is Protandim?
How does Lifevantage support its investors?
What challenges has Lifevantage faced recently?
Who should use Lifevantage products?
What is the Evolve Compensation Plan?
